Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

Repros Therapeutics Inc. (RPRX)

Total paid for Promotions this month: $150,000
E-mails this Month: 2
Estimated Volume Generated: $14,409,358
Research Report on RPRX: Click to see
* The information presented is based on information for Apr , 2016
Tonny Put RPRX on your radar NOW!!  Repros Therapeutics, Inc.  RPRX put it on your Radar! Repros Therapeutics Inc. ® was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. Our current pipeline consists of the following: Enclomiphene Male reproductive health: Enclomiphene ...read more
Promoter: Stockpalooza.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX $150,000 14,409,358
Max Profit: 2.36 % Gain at close: -3.70 %
​​ Start your Pro Trial HERE Remember: Pro members get alerts at least 24 hours before the public.  We offer a 14-day trial of our Pro Membership for $.99. Disclaimer:  Pro Members were alerted to RPRX before the opening bell on Monday at $2.40.    Click HERE to see the full details of our Pro Membership.  Traders,   Our Pro Members did great with RPRX ...read more
Promoter: Penny Stock Superstar Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 2.36 % Gain at close: -3.70 %
    Is this email not displaying correctly? View it in your browser. Take Advantage. Repros Therapeutics, Inc. RPRX We're looking at RPRX as a potential momentum-play this morning. After drastically falling off of a precipice at the end of last month, the stock spent several weeks stepping its way down to a new 52-week low. However, in the few sessions since that time ...read more
Promoter: Blue Horseshoe Stocks Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 7.06 % Gain at close: -6.08 %
    RPRX, Repros Therapeutics Inc.   ** RPRX provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes.   - Statistically significant and clinically relevant improvement in testosterone production observed   - Androxal exhibited dose dependent trends in improvement of indices of gylcemic ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 0.19 % Gain at close: -5.53 %
      RPRX, Repros Therapeutics Inc.   ** RPRX provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes.   - Statistically significant and clinically relevant improvement in testosterone production observed   - Androxal exhibited dose dependent trends in improvement of indices ...read more
Promoter: Stock-pr Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 0.19 % Gain at close: -5.53 %
      RPRX, Repros Therapeutics Inc.   ** RPRX provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes.   - Statistically significant and clinically relevant improvement in testosterone production observed   - Androxal exhibited dose dependent trends in improvement of indices ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 0.19 % Gain at close: -5.53 %
      RPRX, Repros Therapeutics Inc.   ** RPRX provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes.   - Statistically significant and clinically relevant improvement in testosterone production observed   - Androxal exhibited dose dependent trends in improvement of indices ...read more
Promoter: Crweselect.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 0.19 % Gain at close: -5.53 %
      RPRX, Repros Therapeutics Inc.   ** RPRX provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes.   - Statistically significant and clinically relevant improvement in testosterone production observed   - Androxal exhibited dose dependent trends in improvement of indices ...read more
Promoter: Double in stocks Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX Unknown compensation UNKNOWN
Max Profit: 0.19 % Gain at close: -5.53 %
  RPRX, Repros Therapeutics Inc.   ** RPRX reported data from its recently completed ZA-204 study. The oral Androxal achieved equivalent 24 hour average testosterone levels compared to the leading FDA-approved topical gel used per manufacturer’s instructions.   Androxal demonstrated persistent effect, while men on topical gel exhibited numerically lower morning testosterone compared to baseline one week after administration ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX No compensation UNKNOWN
Max Profit: 35.77 % Gain at close: 29.23 %
      RPRX, Repros Therapeutics Inc.   ** RPRX reported data from its recently completed ZA-204 study. The oral Androxal achieved equivalent 24 hour average testosterone levels compared to the leading FDA-approved topical gel used per manufacturer’s instructions.   Androxal demonstrated persistent effect, while men on topical gel exhibited numerically lower morning testosterone compared to baseline one week after ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
RPRX No compensation UNKNOWN
Max Profit: 35.77 % Gain at close: 29.23 %
First  >> Last
Video not found or You must install the Flash Plugin for your Browser in order to view this movie